249 results about "Androgen" patented technology

The invention discloses composite hydrogel as well as a preparation method and application thereof. The curcumin-EGCG composite hydrogel is prepared by forming a complex through hydrogen-bond interaction between gelatin and epigallocatechin gallate and carrying out chemical crosslinking through Schiff base reaction of curcumin and gelatin. The composite hydrogel disclosed by the invention has a self-healing characteristic or viscosity and a shear thinning characteristic, and is beneficial to local application. The composite hydrogel is loose and porous in structure, the drug loading rate can be increased, the drug can be slowly and controllably released, the treatment effect of the composite hydrogel in androgenetic alopecia is promoted, meanwhile, the solubility of a drug monomer can be remarkably improved, and the problem that the drug solubility is low is solved. The composite hydrogel provided by the invention provides an effective transdermal drug delivery preparation for treatment of skin diseases, and has good clinical application prospects and development values.

Embodiments of the present invention provide a pharmaceutical intervention in the neonatal pig that inhibits and delays development and activation of the HPG axis, growth of the boar testis and inhibits testicular production of testosterone and androstenone, which prevents the development of aggressive behavior in the maturing boars and the presence of boar taint in the meat. The invention comprises treatment with a combination of an androgen and an estrogen in the newborn male piglet using extended drug delivery methods, with a defined duration of no more than 12 weeks, for the purpose of inhibiting the production of testosterone and androstenone and the accumulation of the boar taint-inducing molecules androstenone and skatole in the fat.

The invention discloses a product capable of treating androgenetic alopecia and / or promoting hair growth and application of exosomes, the product comprises the product capable of treating androgenetic alopecia and / or promoting hair growth, and is characterized by comprising the exosomes obtained by stimulating mesenchymal stem cells through CHIR99021 and minoxidil combined with the exosomes. The disclosure verifies that the exosome obtained by stimulating mesenchymal stem cells through CHIR99021 can promote hair growth and treat androgenetic alopecia, and particularly, the hair growth effect is better when the exosome is combined with minoxidil, so that a product comprising the exosome and minoxidil can treat androgenetic alopecia and promote hair growth is provided.

The invention relates to application of a platelet reaction protein 4 in preparation of an alopecia medicine, and belongs to the field of medical biology. The invention aims to solve the technical problems of limited curative effect, obvious side effect and narrow application range of the existing alopecia treatment medicine. The invention provides an application of a platelet reaction protein 4 (THBS4) in preparation of an alopecia medicinal preparation, which can promote hair follicles to be converted from a resting period to a growing period by regulating and controlling a mechanical microenvironment around the hair follicles, enhancing the interaction between fibroblasts and hair follicle stem cells and activating regeneration signal channels in hair papilla and hair bud areas. The traditional Chinese medicine composition breaks through the limitation that existing treatment only aims at specific alopecia types, and can be widely applied to various alopecia diseases such as androgenetic alopecia, pressure alopecia and alopecia after chemotherapy. And compared with the traditional medicine, the traditional Chinese medicine composition has the advantages of quick response, no skin irritation reaction and improved hair follicle regeneration efficiency, and provides a brand new solution for safe and efficient treatment of alopecia.

The invention discloses a hybrid vesicle composition containing finasteride and nanogold. The composition is prepared from hair follicle stem cell outer vesicles, lipidosome, finasteride and nanogold, according to the method, the treatment efficiency of finasteride on androgenetic alopecia is enhanced by utilizing the delivery property of a mediated hair recovery mechanism pathway and a homing effect of heterozygous hair follicle stem cell outer vesicles to a hair follicle microenvironment and assisting with a photothermal effect provided by nanogold light conversion, and the method can be widely applied to the fields of medical cosmetology and pharmacy.

The invention relates to the field of biological materials, in particular to a thioketal bond modified 17-type collagen dopamine drug-loaded nanoparticle composite microneedle patch and a preparation method and application thereof, and the microneedle patch is composed of dopamine drug-loaded nanoparticles, thioketal bond modified recombinant 17-type collagen and a polymer substrate. The thioketal bond modified 17-type collagen and polyvinyl alcohol are subjected to physical and chemical double-crosslinking to form hydrogel, then the hydrogel is loaded with drug-loaded nanoparticles, and the hydrogel and a polymer substrate form the ROS and pH value microenvironment double-response collagen microneedle patch loaded with bioactive substances. When the collagen hydrogel is applied to the skin, the tip of the microneedle reaches the area where the hair follicle stem cells exist in a painless and minimally invasive mode, and due to the change of microenvironment molecules in the skin tissue, the breakage of thioketal bonds in the collagen hydrogel can be promoted, so that active oxygen is removed, and the wrapped IGF-1 is released into the hair follicle stem cells; and a potential treatment strategy is provided for androgenetic alopecia.

The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and / or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.

The present invention relates to the topical pharmaceutical composition comprising about 0.001% w / w to about 1% w / w latanoprost and about 1% w / w to about 15% w / w cortexolone-17α-propionate and a pharmaceutically acceptable vehicle comprising one or more solvent and process of its preparation. The invention further relates to the method wherein the composition is suitable for preventing and / or treating hair loss and / or stimulating hair growth. in patients suffering from alopecia, in particular androgenic alopecia (AGA).

The invention provides a method for breeding all-male hybrid pelteobagrus fulvidraco through hybridization of double super-male populations, which comprises the following steps: S1, respectively constructing super-male maintenance lines of pelteobagrus fulvidraco and pelteobagrus vachelli by utilizing a sex reversal technology and a sex molecular marker; s2, carrying out artificial propagation on the maintenance line, and propagating the super male fish in batches; s3, partially replacing estrogen with an androgen antagonist for the propagated supermale fish, and synergistically inducing the supermale fish to obtain superfemale fish; s4, performing specific nutrient enrichment cultivation on the super female fish and the super male parent fish; and S5, carrying out reciprocal cross artificial propagation on the super-female fish and the super-male fish between the two super-male groups to obtain a heterozygous super-male group, namely commercial fry of the all-male hybrid pelteobagrus fulvidraco. According to the technical scheme, super-female fishes can be efficiently induced in batches, high-density breeding of parent fishes is achieved, and the effect and efficiency of artificial breeding are remarkably improved; the bred hybrid all-realgar catfish is high in individual uniformity, the growth speed is increased by 20%, and the male rate reaches 100%.

The invention discloses a hematopoietic preparation for treating androgenetic alopecia and a preparation method of the hematopoietic preparation. The hematopoietic preparation is prepared from 5-30 parts of radix polygoni multiflori preparata, 5-30 parts of wine ligustrum lucidum ait, 5-30 parts of mulberry, 5-30 parts of eclipta, 5-30 parts of radix paeoniae alba, 5-30 parts of astragalus membranaceus and 5-30 parts of rhizoma cibotii. The medicine composition and the specific dosage are obtained through a large number of experimental screening and clinical medication experience screening. The whole formula takes tonifying liver and kidney and benefiting essence and blood as the monarch, and takes tonifying spleen and qi and removing heat to cool blood as the minister and assistant, based on the traditional Chinese medicine theory that essence is stored in kidney and is warmed on hair, by inhibiting DHT generation, resisting hair follicle apoptosis and improving scalp microcirculation, the traditional Chinese medicine composition has the remarkable effect of treating androgenetic alopecia, is weak in toxic and side effects, and can be prepared into various clinical dosage forms.

The present invention relates to methods of predicting the response of prostate cancer subjects to neohelper androgen deprivation therapy. The method is based on prediction results based on gene expression levels identified herein. The present invention provides a method for determining whether neoadjuvant androgen deprivation therapy is useful for a subject and thus should be administered. Further provided is the use of a kit for determining the expression level for predicting the response of a prostate cancer subject to neohelper androgen deprivation therapy.

The invention relates to the technical field of biological medicine, and provides a self-assembly polypeptide with an IGF-1 function and hair growth application thereof, and the self-assembly polypeptide comprises an end-capping group, a self-assembly unit and an insulin-like growth factor C structural domain polypeptide IGF-1C which are connected in sequence. The self-assembled polypeptide with the IGF-1 function, provided by the invention, has a beta-folded secondary structure, and can simulate a binding mode of IGF-1 and an insulin-like growth factor receptor IGF-1R and induce conformational change of an IGF-1R dimer, so that phosphorylation of the IGF-1R is promoted, physiological functions of the IGF-1R are simulated, and growth of hair is promoted. The self-assembled polypeptide with the insulin-like growth factor 1 (IGF-1) function, provided by the invention, can be applied to an alopecia area in a skin smearing manner, and particularly shows an excellent hair growth promoting effect in a mouse physiological alopecia model and an androgenic alopecia model.

The invention discloses a double-chain miRNA, a pharmaceutical composition containing the same, an anti-aging product and application of the double-chain miRNA. The double-stranded miRNA comprises a chemically modified sense strand with a sequence shown as SEQ ID NO: 1 and a chemically modified antisense strand with a sequence shown as SEQ ID NO: 2, wherein the chemical modification of the sense strand and the antisense strand each comprises a 2 '-substituted nucleotide and a modified nucleotide bond; the chemically modified nucleotide bond is at least located at one or more of the 1st-3rd and 20th-23rd sites of the sequence shown as SEQ ID NO: 1 and / or SEQ ID NO: 2. The double-chain miRNA is good in stability and has a remarkable treatment effect on skin cell photoaging, Alzheimer's disease, articular cartilage injury, diabetes, non-alcoholic fatty liver disease, androgenetic alopecia, cirrhosis and chronic nephritis. In short, the effect and the stability of the product are both considered, and the application prospect is good.

The present invention relates to a novel long-acting injectable composition comprising finasteride for the prevention or treatment of androgenetic alopecia. The composition inhibits type II 5α-reductase with a single injection lasting over one month, thereby suppressing the conversion of testosterone to DHT and reducing androgen-mediated follicular miniaturization. In addition, after injection into the body, the average elimination half-life (T1 / 2el) of finasteride can be increased to enhance stability and provide more predictable and uniform therapeutic effects compared to oral formulations.

Disclosed are devices and methods for providing local administration of a sex hormone composition in a mammalian body to promote bone remodeling. The device includes an implantable structure configured for placement at a target intraosseous and / or periosteal site in the mammalian body and an effective amount of a sex hormone composition associated with the implantable structure. The sex hormone composition comprises both an estrogen and an androgen.

The present invention relates to use of a JWA polypeptide in the preparation of a drug for resisting androgenetic alopecia. An amino acid sequence of the polypeptide is shown as I or II: I: FPGSDRF-Z; II: X-FPGSDRF-Z, wherein an amino acid S is subjected to phosphorylation modification, and X and Z are an amino acid or an amino acid sequence, respectively. The described JWA polypeptide can directly target integrin molecules onto hair follicle cells and enter the cells to play a role in regulating and controlling hair follicle proliferation, promoting hair growth and the like; the telogen phase of the hair follicles is significantly shortened, and the anagen phase of the hair follicles is prolonged; the hair shaft and follicle volume is increased; and the expression level of the target cell integrin molecule αvβ1 can be improved, and the hair follicle stem cell signal channel MEK / ERK / E2F1 / SP1 / Wnt10a / 10b / β-catenin can be accurately activated.

The invention relates to an application of an ezetimibe derivative in preparation of an anti-prostatic cancer drug, and belongs to the technical field of medicinal chemistry. The general formula structure of the ezetimibe derivative L14 is # imgabs0. The ezetimibe derivative L14 can be used for preparing new drugs for treating CRPC and NEPC without depending on an androgen receptor pathway, the clinical curative effect is improved, and the clinical drug selection is increased. The micromolecule L14-8 (R1 = R2 =-C (O) CH = CH2) can specifically inhibit proliferation of prostate cancer cells in vitro and can also inhibit growth of prostate tumors in vivo; in the aspect of drug combination, the AR antagonist and the low-dose small molecule L14-8 are combined for use, so that the sensitivity of CRPC and NEPC to the AR antagonist can be remarkably improved, the drug resistance induced by the AR antagonist can be possibly inhibited, and the clinical benefits of the AR antagonist can be improved.

The invention discloses application of vitamin K2 in preparation of an anti-hair loss composition. Research finds that the vitamin K2 has the effects of promoting VEGF gene expression and inhibiting IL-6 and DKK-1 gene expression in an androgen type alopecia model, and has the effects of promoting Gas6, VEGF and TGF gene expression in a pressure type alopecia model, so that a good alopecia prevention and treatment effect is achieved, and toxic and side effects are few.

The invention discloses an anti-hair loss composition containing picea norvegensis leaf extract and application, and relates to the technical field of cosmetics. The composition disclosed by the invention comprises a component A and a component B, wherein the component A comprises the following components in parts by weight: 1-5 parts of a verbasci extract, 0.1-1 part of a saw palmetto extract and 1-5 parts of a picea norvegensis leaf extract; the component B is prepared from the following ingredients in parts by weight: 2 to 4 parts of eucommia ulmoides bark extracts. According to the composition, the verbasci extract, the saw palmetto extract, the picea norvegensis leaf extract and the eucommia ulmoides bark extract are combined to have a synergistic effect, and the composition formed by specific compatibility of the components can prevent androgenetic alopecia from resisting inflammation and bacteria, inhibiting a TRPV3 channel and inhibiting the activity of 5 alpha-reductase; in addition, the plant components are selected, so that the oil-control composition is more suitable for men to use.

The invention discloses a metformin-loaded pegylated two-dimensional phosphorene nanosheet as well as a preparation method and an application of the metformin-loaded pegylated two-dimensional phosphorene nanosheet. The preparation method comprises the following steps: preparing two-dimensional phosphorene nanosheets from black phosphorus crystals through a liquid phase stripping method; the preparation method comprises the following steps: mixing polyethylene glycol amino with a two-dimensional phosphorene nanosheet to prepare a pegylated two-dimensional phosphorene nanosheet; the preparation method comprises the following steps: mixing metformin with the pegylated two-dimensional phosphorene nanosheet, and removing free metformin, so as to obtain the metformin-loaded pegylated two-dimensional phosphorene nanosheet. The metformin-loaded pegylated phosphorene nanosheet disclosed by the invention has transdermal permeation and anti-oxidative stress capabilities, can deliver a drug into skin tissues, induces angiogenesis of hair follicles and promotes hair regeneration of an androgenetic alopecia animal model by removing excessive ROS (reactive oxygen species) in the surrounding environment of the hair follicles, and is degradable, so that the metformin-loaded pegylated phosphorene nanosheet disclosed by the invention has a good application prospect. The compound is safe and low in toxicity, and has good clinical application prospect and development value.

The invention belongs to the technical field of compositions capable of generating foam, and particularly relates to a composition containing a thiohydantoin compound. The composition contains a compound of formula (I) or a pharmaceutically acceptable salt thereof. The foam composition is convenient to use and high in stability, and can be used for treating, preventing or relieving androgen-mediated disorders, diseases or symptoms, such as acne, hirsutism, sebaceous gland enlargement or androgenetic alopecia.

The invention provides an abiraterone derivative as well as a preparation method and application thereof. The abiraterone derivative has a chemical structural formula as shown in a formula (I). The abiraterone derivative disclosed by the invention can be converted into an active substance abiraterone in vivo, has the characteristics of good absorption, good plasma stability, ideal permeable membrane transport capability, good druggability and high safety, and can be used for treating diseases related to excessive androgen. # imgabs0 #

Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.

The present invention discloses the use of schisandra extract in a preparation for preventing and treating hair loss or promoting hair regeneration, belonging to the field of hair loss treatment. The schisandra of the present invention includes a combination of one or more of schisandra A and schisandra B. The present invention found that both schisandra A and schisandra B can significantly promote the proliferation of hair follicle cells; schisandra B can significantly promote hair regeneration after androgenic alopecia, and at the same time, the effect of promoting hair regeneration is related to the concentration of schisandra B. The present invention relates to a drug for treating hair loss, which includes schisandra A and schisandra B and a drug combination, as well as an optional pharmaceutically acceptable carrier. The drug can be prepared into different dosage forms such as external use solution, lotion, liniment, ointment, plaster, paste, patch, etc. for convenient use.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a minoxidil solution for androgenetic alopecia, which takes a deep eutectic solvent as a core solvent system and contains 1.0-5.0% of minoxidil (active ingredient), 0.1-1.0% of preservative, 0.05-1% of stabilizer, a proper amount of sodium hydroxide (the pH value is adjusted to 4-9) and purified water. According to the minoxidil solution, the solubility of minoxidil is greatly improved through the deep eutectic solvent, the solubility of minoxidil reaches 779.85 mg / ml and is 389.9 times that of water, the deep eutectic solvent is used in the minoxidil solution, ethanol is not contained, the dosage of propylene glycol is as low as 3%, ethanol and high-dosage propylene glycol (20%-50%) in a traditional commercially available formula are prevented from being used, irritation to scalp is reduced, and the minoxidil solution is suitable for scalp care. The minoxidil solution is stable in content after 6 months under the condition of 40 DEG C / 60% RH, the in-vitro transdermal performance of the minoxidil solution is superior to that of a commercially available reference preparation of an ethanol and propylene glycol solvent system, and the minoxidil solution also has the advantages of high stability, remarkable hair growth ability and the like.

This invention discloses a method for large-scale breeding of all-female triploid mandarin fish, comprising the following steps: (1) Preparation of all-female diploid fertilized eggs: using male mandarin fish pseudo-males (XX) induced by androgens and female mandarin fish (XX) selected from superior strains as parent fish, collecting sperm and eggs, mixing the two, adding water at a temperature of 28℃ to activate sperm for fertilization, and obtaining all-female diploid fertilized eggs; (2) Heat shock induction of triploids: after the all-female diploid fertilized eggs are fertilized in the above-mentioned water at a temperature of 28℃ for 8 minutes, they are immediately transferred to water at a temperature of 39~41℃ for 1~2 minutes for heat shock induction, and all-female triploid fertilized eggs are obtained; (3) Seedling hatching and cultivation: the fertilized eggs induced by heat shock in step (2) are transferred to the hatching system for hatching, and then conventional seedling cultivation is carried out to obtain all-female triploid mandarin fish seedlings. The mandarin fish fry produced by this method have a high female rate, triploid rate, and survival rate.

The invention discloses 5 alpha-reductase degradation molecules as well as a preparation method and application thereof, four 5 alpha-reductase degradation molecules can realize thorough removal of zymoprotein by inducing proteasome-dependent degradation of 5 alpha-reductase instead of only inhibiting the activity of the 5 alpha-reductase, so that a more lasting treatment effect is obtained; under the condition of equal dosage, the effect of the 5 alpha-reductase degradation molecule on treating the benign prostatic hyperplasia is superior to that of the traditional inhibitor finasteride; the four kinds of 5 alpha-reductase degrading molecules can effectively degrade 5 alpha-reductase protein and remarkably inhibit development of benign prostatic hyperplasia, have good biological safety and provide new strategies and candidate drugs for treatment of diseases related to 5 alpha-reductase such as benign prostatic hyperplasia, prostatic cancer, androgenetic alopecia and acne.

The invention discloses an ionic liquid for treating androgen-derived alopecia as well as a preparation method and application thereof, and belongs to the technical field of medicines. Through the composite molecular structure design of the quaternary ammonium salt-taurine ionic liquid, the ionic liquid integrates ROS removal, stem cell activation, efficient transdermal and long-acting retention, so that the ionic liquid can directly act on a core pathological link of androgen-derived alopecia; and safe and efficient treatment without drug combination is effectively achieved.

This invention belongs to the fields of biomedicine and cosmetics, and discloses the application of holly glycoside in promoting hair growth and preventing hair loss. Holly glycoside promotes the transition of hair follicles from the telogen phase to the anagen phase (i.e., shortening the telogen phase and prolonging the anagen phase), and inhibits cyclophosphamide-induced apoptosis of hair follicle cells and DHT-induced miniaturization of hair follicles. In androgenetic alopecia, telogen effluvium, and chemical alopecia models, its hair growth-promoting effect is comparable to that of the positive control drug minoxidil. It has broad application prospects in pharmaceutical formulations, cosmetics, skincare products, and beauty products.